Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt. Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI?s first marketed product is Sci-B-Vac?, a hepatitis B (?HBV?) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI?s eVLP Platform technology allows for the development of enveloped (?e?) virus-like particle (?VLP?) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (?CMV?) and glioblastoma multiforme (?GBM?). VBI is also advancing its LPV? Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel..
Researchers Explore the Mechanisms by Which CMV Infection May Impact Fetal Brain Development
Congenital cytomegalovirus (?CMV?) infection is a leading prenatal cause of intellectual disability, nonhereditary sensorineural hearing loss, and can bring about other long-term neurodevelopmental disabilities including cerebral palsy, vision impairment, and seizures..
VBI Vaccines: Solid Drug Pipeline Backed By Key Investors That Control Billions
Summary > VBI Vaccines recently completed a merger that brings together several important biotech investors. > The new entity now owns a diversified drug pipeline and several technology platforms. > The stock trades at a discount to where some of the top biotech investors recently invested in VBI Vaccines.
Despite taking positive steps by completing a merger, finalizing another financing round and having an impressive owner roster, VBI Vaccines (NASDAQ:VBIV) still remains relatively unknown. As the company states, the new entity creates a commercial stage biotech with an approved hepatitis B vaccine, a pipeline of preventative and therapeutic vaccine candidates, and two novel technology platforms..
VBI Vaccines Appoints Dr. Francisco Diaz-Mitoma as Chief Medical Officer
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (?VBI?) is pleased to announce the appointment of Dr. Francisco Diaz-Mitoma, M.D., Ph.D., as Chief Medical Officer. In his new position, Dr. Diaz-Mitoma will oversee clinical development initiatives at VBI.
Dr. Diaz-Mitoma is a renowned medical scientist and infectious disease researcher who has been involved in the clinical development of nine licensed vaccines, and has actively participated in more than 50 antiviral and vaccine clinical trials. He has also authored more than 130 scientific papers and textbook chapters..
VBI VACCINES, INC. - CMV Vaccine and Immune Oncology Platform Drive Value; Initiating Coverage at Buy
We are initiating coverage of VBI Vaccines Inc. (Nasdaq: VBIV, TSX: VBV) with a BUY rating and $7.00 price target. We view VBIV as both an emerging vaccine development story and a restructuring story. The company has moved quickly in the past 12 months to significantly de-risk its business model through; 1) the addition of commercial-stage product to support near-term revenue and gross profit growth, 2) leveraging the in-house eVLP platform to expand its prophylactic vaccine pipeline, and 3) entering therapeutic vaccine develop with a lead immuno-oncology product for treatment of glioblastoma (GBM). Near-term milestones include: 1) unveiling design for European registration studies for the company?s Sci-B-Vac for prevention of HBV and 2) completing an interim analysis of a potential first-in-class vaccine for prevention of CMV infections. By our estimates Sci-B-Vac has peak revenue potential of $200M while peak sales for the CMV program could exceed $700M. Our $7.00 PT is based on a DCF analysis assuming a 25% discount rate, 41 million shares on a fully diluted basis, terminal year (2025) FCF of $92M and 15% long-term growth rate..
VBI Vaccines to Present at the Ladenburg Thalmann Healthcare Conference
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (?VBI?) is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The event is being held at the Sofitel New York Hotel in New York, NY.
During the presentation, Jeff Baxter, VBI?s President and CEO, will provide an overview of VBI and its platform technologies, and will summarize recent developments in the company?s pipeline of vaccine candidates.
* Deutsche Bank Real-Time Indikationen basieren auf Preisen von der Deutschen Bank emittierten Produkten. Diese Produkte versuchen, den jeweiligen Index 1:1 zu tracken.
Die Preisstellung erfolgt börsentäglich zwischen 09:15 und 17:15.